Rationale and results behind the use of breakthrough therapy-designated E-selectin antagonist for AML

Rationale and results behind the use of breakthrough therapy-designated E-selectin antagonist for AML

VJHemOnc

1 year
100 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
The binding of E-selectin to leukemic cells has been shown to promote cell survival and chemotherapy resistance in acute myeloid leukemia (AML). In this interview, Daniel DeAngelo, MD, PhD, of Dana-Farber Cancer Institute, Boston, MA, discusses a novel therapeutic that is antagonistic towards E-selectin, GMI-1271. Dr DeAngelo discusses the rationale behind the mechanism of action of this drug and the results of the trial investigating this agent (NCT02306291), which he presented at the American Society of Hematology (ASH) 2017 Annual Meeting and Exposition in Atlanta, GA.
Up Next Autoplay
How Does This Affect Clinicians Today?
How Does This Affect Clinicians Today?
Category: Breast Cancer
0 Views
Cancer-News 7 minutes
Measuring Chromatin Accessibility: How Reliable is This Data?
Measuring Chromatin Accessibility: How Reliable is This Data?
Category: Breast Cancer
0 Views
Cancer-News 29 minutes
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Dual-function Virus Designed For Killing Tumor Cells and Helping Immune Cells
Category: Melanoma and Skin Cancer
1 Views
Cancer-News 1 hour
Mapping the usual breast development to recognize cancer better
Mapping the usual breast development to recognize cancer better
Category: Breast Cancer
2 Views
Cancer-News 2 hours
Metformin: How Does This Affect Treatment?
Metformin: How Does This Affect Treatment?
Category: Ovarian Cancer
2 Views
Cancer-News 2 hours
New Frontier Possibility for Preventing Ovarian Cancer
New Frontier Possibility for Preventing Ovarian Cancer
Category: Ovarian Cancer
1 Views
Cancer-News 2 hours
"Wild idea" opens possible new boundaries to ovarian cancer prevention
Category: Ovarian Cancer
3 Views
Cancer-News 2 hours
Personalized Algorithms: How is this different?
Personalized Algorithms: How is this different?
Category: Immunotherapy
4 Views
Cancer-News 23 hours
Algorithm Personalizing Best Targets for Immunotherapy
Algorithm Personalizing Best Targets for Immunotherapy
Category: Immunotherapy
3 Views
Cancer-News 23 hours
Algorithm personalizes the best targets for immunotherapy for cancer mutations.
Algorithm personalizes the best targets for immunotherapy for cancer mutations.
Category: Immunotherapy
5 Views
Cancer-News 23 hours